메뉴 건너뛰기




Volumn 24, Issue 6, 2012, Pages 742-747

Advances in the management of follicular lymphoma

Author keywords

CD20; follicular lymphoma; lymphoma therapy; monoclonal antibody

Indexed keywords

ALPHA2 INTERFERON; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BENDAMUSTINE; BLINATUMOMAB; BREAKPOINT CLUSTER REGION PROTEIN; CD19 ANTIBODY; CD20 ANTIBODY; CD22 ANTIGEN; CD23 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CD74 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; PRO 131921; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

EID: 84868205105     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358f602     Document Type: Review
Times cited : (11)

References (57)
  • 1
    • 1842413105 scopus 로고    scopus 로고
    • The Non-Hodgkin's Lymphoma Classification Project
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
    • (1997) Blood , vol.89 , pp. 3909-3918
  • 2
    • 79958261904 scopus 로고    scopus 로고
    • The microenvironment in follicular lymphoma
    • de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24:135-146.
    • (2011) Best Pract Res Clin Haematol , vol.24 , pp. 135-146
    • De Jong, D.1    Fest, T.2
  • 3
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
    • McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
    • (1998) J Clin Oncol , vol.16 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-Lopez, A.J.2    Link, B.K.3
  • 4
    • 34249939116 scopus 로고    scopus 로고
    • Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study
    • Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25:1986-1992.
    • (2007) J Clin Oncol , vol.25 , pp. 1986-1992
    • Herold, M.1    Haas, A.2    Srock, S.3
  • 5
    • 53749085410 scopus 로고    scopus 로고
    • Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    • Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579-4586.
    • (2008) J Clin Oncol , vol.26 , pp. 4579-4586
    • Marcus, R.1    Imrie, K.2    Solal-Celigny, P.3
  • 6
    • 28544435078 scopus 로고    scopus 로고
    • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-3732.
    • (2005) Blood , vol.106 , pp. 3725-3732
    • Hiddemann, W.1    Kneba, M.2    Dreyling, M.3
  • 7
    • 58149386408 scopus 로고    scopus 로고
    • Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study
    • Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-4831.
    • (2008) Blood , vol.112 , pp. 4824-4831
    • Salles, G.1    Mounier, N.2    De Guibert, S.3
  • 8
    • 78650823247 scopus 로고    scopus 로고
    • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial
    • Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42-51.
    • (2011) Lancet , vol.377 , pp. 42-51
    • Salles, G.1    Seymour, J.F.2    Offner, F.3
  • 9
    • 0021703548 scopus 로고
    • The natural history of initially untreated low-grade non-Hodgkin's lymphomas
    • Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471-1475.
    • (1984) N Engl J Med , vol.311 , pp. 1471-1475
    • Horning, S.J.1    Rosenberg, S.A.2
  • 10
    • 0023992626 scopus 로고
    • The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment
    • Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25 (2 Suppl 2):11-16.
    • (1988) Semin Hematol , vol.25 , Issue.2 SUPPL. 2 , pp. 11-16
    • Young, R.C.1    Longo, D.L.2    Glatstein, E.3
  • 11
    • 0031050192 scopus 로고    scopus 로고
    • Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte
    • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15:1110-1117.
    • (1997) J Clin Oncol , vol.15 , pp. 1110-1117
    • Brice, P.1    Bastion, Y.2    Lepage, E.3
  • 12
    • 0041656437 scopus 로고    scopus 로고
    • Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: A randomised controlled trial
    • Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516-522.
    • (2003) Lancet , vol.362 , pp. 516-522
    • Ardeshna, K.M.1    Smith, P.2    Norton, A.3
  • 13
    • 0035169514 scopus 로고    scopus 로고
    • Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
    • Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
    • (2001) Blood , vol.97 , pp. 101-106
    • Colombat, P.1    Salles, G.2    Brousse, N.3
  • 14
    • 78951481506 scopus 로고    scopus 로고
    • An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (Grades 1, 2 and 3a) A preliminary analysis
    • Ardeshna K, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis. Blood 2010; 116:6.
    • (2010) Blood , vol.116 , pp. 6
    • Ardeshna, K.1    Qian, W.2    Smith, P.3
  • 15
    • 62449324950 scopus 로고    scopus 로고
    • Follicular lymphoma in the United States: First report of the national Lympho Care study
    • Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national Lympho Care study. J Clin Oncol 2009; 27:1202-1208.
    • (2009) J Clin Oncol , vol.27 , pp. 1202-1208
    • Friedberg, J.W.1    Taylor, M.D.2    Cerhan, J.R.3
  • 16
    • 34249704600 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
    • Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 706-714
    • Schulz, H.1    Bohlius, J.F.2    Trelle, S.3
  • 17
    • 77649225344 scopus 로고    scopus 로고
    • Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte
    • Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 2010; 28:822-829.
    • (2010) J Clin Oncol , vol.28 , pp. 822-829
    • Bachy, E.1    Brice, P.2    Delarue, R.3
  • 18
    • 43249117980 scopus 로고    scopus 로고
    • Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage
    • Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111:4004-4013.
    • (2008) Blood , vol.111 , pp. 4004-4013
    • Ladetto, M.1    De Marco, F.2    Benedetti, F.3
  • 19
    • 77951453410 scopus 로고    scopus 로고
    • Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study
    • Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2011; 115:3215-3223.
    • (2011) Blood , vol.115 , pp. 3215-3223
    • Pott, C.1    Hoster, E.2    Delfau-Larue, M.H.3
  • 20
    • 38349119981 scopus 로고    scopus 로고
    • Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
    • Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204-210.
    • (2008) J Clin Oncol , vol.26 , pp. 204-210
    • Friedberg, J.W.1    Cohen, P.2    Chen, L.3
  • 21
    • 74549225036 scopus 로고    scopus 로고
    • Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a Multicenter Study
    • Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2011; 116:106-114.
    • (2011) Cancer , vol.116 , pp. 106-114
    • Kahl, B.S.1    Bartlett, N.L.2    Leonard, J.P.3
  • 22
    • 20644469242 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
    • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-3389.
    • (2005) J Clin Oncol , vol.23 , pp. 3383-3389
    • Rummel, M.J.1    Al-Batran, S.E.2    Kim, S.Z.3
  • 23
    • 77950488976 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is superior in respect of progression free survival and complete remission rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced Follicular, indolent, and Mantle Cell Lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
    • abstract405
    • Rummel JR, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and complete remission rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced Follicular, indolent, and Mantle Cell Lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:abstract405.
    • (2009) Blood , vol.114
    • Rummel, J.R.1    Niederle, N.2    Maschmeyer, G.3
  • 24
    • 0033625248 scopus 로고    scopus 로고
    • Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809
    • Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18:2010-2016.
    • (2000) J Clin Oncol , vol.18 , pp. 2010-2016
    • Fisher, R.I.1    Dana, B.W.2    Leblanc, M.3
  • 25
    • 0344157390 scopus 로고    scopus 로고
    • Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization
    • Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16:1538-1546.
    • (1998) J Clin Oncol , vol.16 , pp. 1538-1546
    • Arranz, R.1    Garcia-Alfonso, P.2    Sobrino, P.3
  • 26
    • 0007884202 scopus 로고    scopus 로고
    • Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
    • Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16:41-47.
    • (1998) J Clin Oncol , vol.16 , pp. 41-47
    • Hagenbeek, A.1    Carde, P.2    Meerwaldt, J.H.3
  • 27
    • 2942567554 scopus 로고    scopus 로고
    • Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule
    • Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-4423.
    • (2004) Blood , vol.103 , pp. 4416-4423
    • Ghielmini, M.1    Schmitz, S.F.2    Cogliatti, S.B.3
  • 28
    • 14544276412 scopus 로고    scopus 로고
    • Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: A randomized phase II trial of the Minnie Pearl Cancer Research Network
    • Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088-1095.
    • (2005) J Clin Oncol , vol.23 , pp. 1088-1095
    • Hainsworth, J.D.1    Litchy, S.2    Shaffer, D.W.3
  • 29
    • 77956413908 scopus 로고    scopus 로고
    • Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
    • van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-2858.
    • (2010) J Clin Oncol , vol.28 , pp. 2853-2858
    • Van Oers, M.H.1    Van Glabbeke, M.2    Giurgea, L.3
  • 30
    • 83255176958 scopus 로고    scopus 로고
    • Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and metaanalysis of randomized trials
    • Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and metaanalysis of randomized trials. J Natl Cancer Inst 2011; 103:1799-1806.
    • (2011) J Natl Cancer Inst , vol.103 , pp. 1799-1806
    • Vidal, L.1    Gafter-Gvili, A.2    Salles, G.3
  • 31
    • 84867400613 scopus 로고    scopus 로고
    • Results of eastern cooperative oncology group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma
    • LBA-6
    • Kahl BS, Hong F, Williams ME, et al. Results of eastern cooperative oncology group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118:LBA-6.
    • (2011) Blood , vol.118
    • Kahl, B.S.1    Hong, F.2    Williams, M.E.3
  • 32
    • 84855438011 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia
    • Herold T, Seiler T, Egensperger R, et al. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2011; 53:169-172.
    • (2011) Leuk Lymphoma , vol.53 , pp. 169-172
    • Herold, T.1    Seiler, T.2    Egensperger, R.3
  • 33
    • 27544508559 scopus 로고    scopus 로고
    • Tolerability and safety of rituximab (MabThera)
    • Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
    • (2005) Cancer Treat Rev , vol.31 , pp. 456-473
    • Kimby, E.1
  • 34
    • 0037306946 scopus 로고    scopus 로고
    • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    • Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045-1052.
    • (2003) Blood , vol.101 , pp. 1045-1052
    • Cragg, M.S.1    Morgan, S.M.2    Chan, H.T.3
  • 35
    • 84857327275 scopus 로고    scopus 로고
    • Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell Non-Hodgkin Lymphoma: Preliminary analysis of the GAUSS study
    • Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell Non-Hodgkin Lymphoma: preliminary analysis of the GAUSS study. Blood 2011; 118:269.
    • (2011) Blood , vol.118 , pp. 269
    • Sehn, L.H.1    Goy, A.2    Offner, F.C.3
  • 36
    • 79955979273 scopus 로고    scopus 로고
    • Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies
    • Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies. Blood 2011; 117:4519-4529.
    • (2011) Blood , vol.117 , pp. 4519-4529
    • Alduaij, W.1    Ivanov, A.2    Honeychurch, J.3
  • 37
    • 77951561987 scopus 로고    scopus 로고
    • Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
    • Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-4402.
    • (2010) Blood , vol.115 , pp. 4393-4402
    • Mossner, E.1    Brunker, P.2    Moser, S.3
  • 38
    • 78651354250 scopus 로고    scopus 로고
    • Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
    • Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152:295-306.
    • (2011) Br J Haematol , vol.152 , pp. 295-306
    • Patz, M.1    Isaeva, P.2    Forcob, N.3
  • 39
    • 78751564397 scopus 로고    scopus 로고
    • Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101
    • Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the antilymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10:178-185.
    • (2011) Mol Cancer Ther , vol.10 , pp. 178-185
    • Dalle, S.1    Reslan, L.2    Besseyre De Horts, T.3
  • 40
    • 84861835530 scopus 로고    scopus 로고
    • Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    • Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126-5132.
    • (2012) Blood , vol.119 , pp. 5126-5132
    • Salles, G.1    Morschhauser, F.2    Lamy, T.3
  • 41
    • 79961240865 scopus 로고    scopus 로고
    • Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: Updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL)
    • Salles GA, Morschhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). Blood 2010; 116:2868.
    • (2010) Blood , vol.116 , pp. 2868
    • Salles, G.A.1    Morschhauser, F.2    Thieblemont, C.3
  • 42
    • 0031080328 scopus 로고    scopus 로고
    • CD22 is a negative regulator of B-cell receptor signalling
    • Nitschke L, Carsetti R, Ocker B, et al. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997; 7:133-143.
    • (1997) Curr Biol , vol.7 , pp. 133-143
    • Nitschke, L.1    Carsetti, R.2    Ocker, B.3
  • 43
    • 0042413843 scopus 로고    scopus 로고
    • Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    • Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051-3059.
    • (2003) J Clin Oncol , vol.21 , pp. 3051-3059
    • Leonard, J.P.1    Coleman, M.2    Ketas, J.C.3
  • 44
    • 33748471355 scopus 로고    scopus 로고
    • Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
    • Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:3880-3886.
    • (2006) J Clin Oncol , vol.24 , pp. 3880-3886
    • Strauss, S.J.1    Morschhauser, F.2    Rech, J.3
  • 45
    • 80054098574 scopus 로고    scopus 로고
    • Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    • Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011; 118:4053-4061.
    • (2011) Blood , vol.118 , pp. 4053-4061
    • Micallef, I.N.1    Maurer, M.J.2    Wiseman, G.A.3
  • 46
    • 67650346177 scopus 로고    scopus 로고
    • Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
    • Rossi EA, Goldenberg DM, Cardillo TM, et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-6171.
    • (2009) Blood , vol.113 , pp. 6161-6171
    • Rossi, E.A.1    Goldenberg, D.M.2    Cardillo, T.M.3
  • 47
    • 41349118741 scopus 로고    scopus 로고
    • Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
    • Qu Z, Goldenberg DM, Cardillo TM, et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111:2211-2219.
    • (2008) Blood , vol.111 , pp. 2211-2219
    • Qu, Z.1    Goldenberg, D.M.2    Cardillo, T.M.3
  • 48
    • 77957272703 scopus 로고    scopus 로고
    • High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma
    • Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:3709-3716.
    • (2010) J Clin Oncol , vol.28 , pp. 3709-3716
    • Morschhauser, F.1    Kraeber-Bodere, F.2    Wegener, W.A.3
  • 49
    • 77951648118 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase i study
    • Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28:2085-2093.
    • (2010) J Clin Oncol , vol.28 , pp. 2085-2093
    • Advani, A.1    Coiffier, B.2    Czuczman, M.S.3
  • 50
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-977.
    • (2008) Science , vol.321 , pp. 974-977
    • Bargou, R.1    Leo, E.2    Zugmaier, G.3
  • 51
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115:2578-2585.
    • (2010) Blood , vol.115 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3
  • 52
    • 78649797979 scopus 로고    scopus 로고
    • Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase i study
    • Advani R, Sharman JP, Smith SM, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol 2010; 28 (15s):8012.
    • (2010) J Clin Oncol , vol.28 , Issue.15 S , pp. 8012
    • Advani, R.1    Sharman, J.P.2    Smith, S.M.3
  • 53
    • 79958248822 scopus 로고    scopus 로고
    • Clinical activity in a phase 1 study of CAL-101 an isoform-selective inhibitor of phophatidylinositol 2-Kinase p110delta in patients with B-cell malignancies
    • Brown J, Byrd J, Furman R, et al. Clinical activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phophatidylinositol 2-Kinase p110delta, in patients with B-cell malignancies. Haematologica 2010; 95 (s2):466.
    • (2010) Haematologica , vol.95 , Issue.S2 , pp. 466
    • Brown, J.1    Byrd, J.2    Furman, R.3
  • 54
    • 51649123319 scopus 로고    scopus 로고
    • Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+ tumor cells
    • Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+ tumor cells. Clin Cancer Res 2008; 14:4650-4657.
    • (2008) Clin Cancer Res , vol.14 , pp. 4650-4657
    • Wu, L.1    Adams, M.2    Carter, T.3
  • 55
    • 73949145763 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    • Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27:5404-5409.
    • (2009) J Clin Oncol , vol.27 , pp. 5404-5409
    • Witzig, T.E.1    Wiernik, P.H.2    Moore, T.3
  • 56
    • 79952947321 scopus 로고    scopus 로고
    • R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL)
    • abstract1679
    • Dutia M, DeRoock I, Chee K, et al. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent Non-Hodgkin's Lymphoma (NHL). Blood 2009; 114:abstract1679.
    • (2009) Blood , pp. 114
    • Dutia, M.1    Deroock, I.2    Chee, K.3
  • 57
    • 79952853727 scopus 로고    scopus 로고
    • Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma
    • abstract8036
    • Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:abstract8036.
    • (2010) J Clin Oncol , vol.28
    • Fowler, N.H.1    McLaughlin, P.2    Hagemeister, F.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.